Evotec
Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.
Latest Content
    Evotec Announces Key Progress in Neuroscience Collaboration With Bristol Myers Squibb
    The Promise of Continuous Processing To Advance Biopharmaceutical Production
    Innovations in Biopharma 2025
    Evotec Receives Grant From Korean Government To Develop Novel Antibody-Based Treatments for Lung Diseases
    Evotec SE Announces First Projects for LAB eN² Drug Discovery Accelerator With Novo Nordisk
    Spatial Transcriptomics in Neuroscience
    Harnessing Structural Insights in Drug Discovery
    Therapeutic siRNAs: Considerations for “Picking the Best One”
    Trends in Target-Based Drug Discovery